2095486-67-0
2095486-67-0
Chemical Structure
eIF4A3-IN-1
- CAS No.: 2095486-67-0
- Formula:C29H23BrClN5O2
- Molecular Weight:588.88
IUPAC Name: (S)-3-(4-(4-(4-bromobenzoyl)-3-(4-chlorophenyl)piperazine-1-carbonyl)-5-methyl-1H-pyrazol-1-yl)benzonitrile
InChIKey: BDGKKHWJYBQRIE-HHHXNRCGSA-N
SMILES: ClC(C=C1)=CC=C1[C@@H]2N(C(C3=CC=C(Br)C=C3)=O)CCN(C(C4=C(C)N(C5=CC=CC(C#N)=C5)N=C4)=O)C2
Biological Activity: eIF4A3-IN-1 is a selective eIF4A3 inhibitor (IC50: 0.26 μM; Kd: 0.043 μM) with cellular nonsense-mediated RNA decay (NMD) inhibitory activity. eIF4A3-IN-1 can specifically bind to the non-ATP binding site of eIF4A3. eIF4A3-IN-1 has anti-tumor and analgesic activities[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
eIF4A3-IN-1 | 99.96% | eIF4A3-IN-1 is a selective eIF4A3 inhibitor (IC50: 0.26 μM; Kd: 0.043 μM) with cellular nonsense-mediated RNA decay (NMD) inhibitory activity. eIF4A3-IN-1 can specifically bind to the non-ATP binding site of eIF4A3. eIF4A3-IN-1 has anti-tumor and analgesic activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
eIF4A3-IN-1 (Standard) | ≥98% | eIF4A3-IN-1 (Standard) is the analytical standard of eIF4A3-IN-1 (HY-101513). This product is intended for research and analytical applications. eIF4A3-IN-1 is a selective eIF4A3 inhibitor (IC50: 0.26 μM; Kd: 0.043 μM) with cellular nonsense-mediated RNA decay (NMD) inhibitory activity. eIF4A3-IN-1 can specifically bind to the non-ATP binding site of eIF4A3. eIF4A3-IN-1 has anti-tumor and analgesic activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Ito M, et al. Discovery of Novel 1,4-Diacylpiperazines as Selective and Cell-Active eIF4A3 Inhibitors. J Med Chem. 2017 Apr 27;60(8):3335-3351. [Content Brief]
- [2]. López-Cánovas JL, et al. Spliceosomal profiling identifies EIF4A3 as a novel oncogene in hepatocellular carcinoma acting through the modulation of FGFR4 splicing. Clin Transl Med. 2022 Nov;12(11):e1102. [Content Brief]
- [3]. Hsieh MC, et al. Phosphorylated Upstream Frameshift 1-dependent Nonsense-mediated μ-Opioid Receptor mRNA Decay in the Spinal Cord Contributes to the Development of Neuropathic Allodynia-like Behavior in Rats. Anesthesiology. 2023 Jun 1;138(6):634-655. [Content Brief]
